83 related articles for article (PubMed ID: 2318551)
41. Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics.
Brøsen K; Gram LF; Klysner R; Bech P
Eur J Clin Pharmacol; 1986; 30(1):43-9. PubMed ID: 3709631
[TBL] [Abstract][Full Text] [Related]
42. Population pharmacokinetics of imipramine in children.
Tamayo M; Fernández de Gatta MM; García MJ; Domínguez-Gil A
Eur J Clin Pharmacol; 1992; 43(1):89-92. PubMed ID: 1505617
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics of imipramine are affected by age and sex in rats.
Wilson MA; Roy EJ
Life Sci; 1986 Feb; 38(8):711-8. PubMed ID: 3951327
[TBL] [Abstract][Full Text] [Related]
44. Improving Biopharmaceutical Properties of Vinpocetine Through Cocrystallization.
Golob S; Perry M; Lusi M; Chierotti MR; Grabnar I; Lassiani L; Voinovich D; Zaworotko MJ
J Pharm Sci; 2016 Dec; 105(12):3626-3633. PubMed ID: 27789032
[TBL] [Abstract][Full Text] [Related]
45. Simultaneous analysis of imipramine and its metabolite desipramine in biological fluids.
Craig JC; Gruenke LD; Nguyen TL
J Chromatogr; 1982 Apr; 239():81-6. PubMed ID: 7096509
[TBL] [Abstract][Full Text] [Related]
46. Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers.
Ciraulo DA; Barnhill JG; Jaffe JH
Clin Pharmacol Ther; 1988 May; 43(5):509-18. PubMed ID: 3365915
[TBL] [Abstract][Full Text] [Related]
47. Effect of different doses of borneol on the pharmacokinetics of vinpocetine in rat plasma and brain after intraocular administration.
Ma Q; Dai M; Zhang H; Bai L; He N
Xenobiotica; 2020 May; 50(5):580-587. PubMed ID: 31424307
[TBL] [Abstract][Full Text] [Related]
48. Modelling of non-linear pharmacokinetics in sheep after short-term infusion of cardiotoxic doses of imipramine.
Meineke I; Schmidt W; Nottrott M; Schröder T; Hellige G; Gundert-Remy U
Pharmacol Toxicol; 1997 Jun; 80(6):266-71. PubMed ID: 9225362
[TBL] [Abstract][Full Text] [Related]
49. Effect of age on the pharmacokinetics of vinpocetine (Cavinton) and apovincaminic acid.
Miskolczi P; Vereczkey L; Szalay L; Göndöc C
Eur J Clin Pharmacol; 1987; 33(2):185-9. PubMed ID: 3691609
[TBL] [Abstract][Full Text] [Related]
50. Vinpocetine (A comprehensive profile).
Khalil NY; Bakheit AH; Alkahtani HM; Al-Muhanna T
Profiles Drug Subst Excip Relat Methodol; 2022; 47():1-54. PubMed ID: 35396012
[TBL] [Abstract][Full Text] [Related]
51. Vinpocetine, cognition, and epilepsy.
Meador KJ; Leeman-Markowski B; Medina AE; Illamola SM; Seliger J; Novak G; Lin C; Ivanisevic M; Razavi B; Marino S; Boyd A; Loring DW
Epilepsy Behav; 2021 Jun; 119():107988. PubMed ID: 33957389
[TBL] [Abstract][Full Text] [Related]
52. Vinpocetine effects on cognitive impairments produced by flunitrazepam.
Bhatti JZ; Hindmarch I
Int Clin Psychopharmacol; 1987 Oct; 2(4):325-31. PubMed ID: 3693872
[TBL] [Abstract][Full Text] [Related]
53. Vinpocetine improved neuropsychiatric and epileptic outcomes in a patient with a GABRA1 loss-of-function variant.
Gjerulfsen CE; Mieszczanek TS; Johannesen KM; Liao VWY; Chebib M; Nørby HAJ; Gardella E; Rubboli G; Ahring P; Møller RS
Ann Clin Transl Neurol; 2023 Aug; 10(8):1493-1498. PubMed ID: 37434477
[TBL] [Abstract][Full Text] [Related]
54. Synthesis and Activity Evaluation of Vinpocetine-Derived Indole Alkaloids.
Dong ZC; Shi Y; Zheng LL; Tian YP; Yang J; Wei Y; Zhou Y; Pan BW
Molecules; 2023 Dec; 29(1):. PubMed ID: 38202595
[TBL] [Abstract][Full Text] [Related]
55. Vinpocetine: An Unapproved Drug Sold as a Dietary Supplement.
Cohen PA
Mayo Clin Proc; 2015 Oct; 90(10):1455. PubMed ID: 26434971
[No Abstract] [Full Text] [Related]
56. Desipramine: cardiovascular effects and plasma levels.
Rudorfer MV; Young RC
Am J Psychiatry; 1980 Aug; 137(8):984-6. PubMed ID: 7416309
[No Abstract] [Full Text] [Related]
57. IMIPRAMINE-DESMETHYLIMIPRAMINE. A PHARMACOLOGICAL STUDY ON HUMAN BEINGS.
IDESTROEM CM; CADENIUS B
Psychopharmacologia; 1964 Jun; 5():431-9. PubMed ID: 14194687
[No Abstract] [Full Text] [Related]
58. Clinical Pharmacology of Vinpocetine: Properties Revisited and Introduction of a Population Pharmacokinetic Model for Its Metabolite, Apovincaminic Acid (AVA).
Petric Z; Paixão P; Filipe A; Guimarães Morais J
Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896263
[TBL] [Abstract][Full Text] [Related]
59. Prediction of steady state plasma concentration of imipramine [proceedings].
Potter WZ; Zavadil AP; Goodwin FK
Psychopharmacol Bull; 1978 Jul; 14(3):29-33. PubMed ID: 674532
[No Abstract] [Full Text] [Related]
60. Pharmacokinetics of vinpocetine and its metabolite, apovincaminic acid, in plasma and cerebrospinal fluid after intravenous infusion.
Polgár M; Vereczkey L; Nyáry I
J Pharm Biomed Anal; 1985; 3(2):131-9. PubMed ID: 16867695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
